10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||||||||||||
| |||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
REGENERON PHARMACEUTICALS, INC. | |||
Ticker: REGN Fiscal Year: 2014 | |||
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME | |||
Period Ending Dec 31, 2014 10-K (Filed: Feb 12, 2015) | |||
| (In Thousands) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | |
| Income Statement [Abstract] | |||
| Revenues: | |||
| Net product sales | $ 1,750,762 | 1,425,839 | 858,093 |
| Sanofi collaboration revenue | 541,299 | 430,111 | 423,814 |
| Bayer HealthCare collaboration revenue | 495,555 | 220,289 | 70,099 |
| Technology licensing and other revenue | 31,941 | 28,506 | 26,471 |
| Total revenues | 2,819,557 | 2,104,745 | 1,378,477 |
| Expenses: | |||
| Research and development | 1,271,353 | 859,947 | 625,554 |
| Selling, general, and administrative | 504,755 | 329,415 | 210,755 |
| Cost of goods sold | 129,030 | 118,048 | 83,927 |
| Cost of collaboration manufacturing | 75,988 | 37,307 | 528 |
| Total expenses | 1,981,126 | 1,344,717 | 920,764 |
| Income from operations | 838,431 | 760,028 | 457,713 |
| Other income (expense): | |||
| Investment and other income (expense) | 8,157 | (231) | 2,012 |
| Interest expense | (37,372) | (46,437) | (45,304) |
| Loss on Extinguishment of Debt | (33,469) | 0 | 0 |
| Total other income (expense) | (62,684) | (46,668) | (43,292) |
| Income before income taxes | 775,747 | 713,360 | 414,421 |
| Income tax (expense) benefit | (427,673) | (288,998) | 335,848 |
| Net income | 348,074 | 424,362 | 750,269 |
| Net income per share - basic | 3.46 | 4.33 | 7.92 |
| Net income per share - diluted | 3.07 | 3.81 | 6.75 |
| Weighted average shares outstanding - basic | 100,612 | 97,917 | 94,685 |
| Weighted average shares outstanding - diluted | 113,413 | 111,290 | 115,382 |
| Statements of Comprehensive Income | |||
| Net income | 348,074 | 424,362 | 750,269 |
| Other comprehensive income: | |||
| Unrealized gain (loss) on marketable securities, net of tax | 53,439 | (22) | 696 |
| Comprehensive income | 401,513 | 424,340 | 750,965 |
| External Links | |
| REGENERON PHARMACEUTICALS, INC. (REGN) Fiscal Year 2014 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |